Advancing Newborn Screening for Sickle Cell Disease in Africa

By Crystal Lubbe

January 7, 2025

Newborn Screening for Sickle Cell Disease (SCD) in Africa

Newborn screening for Sickle Cell Disease (SCD) is a vital intervention in combating this severe health issue in Africa. The Consortium on Newborn Screening in Africa (CONSA), initiated by the American Society of Hematology (ASH), is a critical program aimed at implementing newborn screening and early interventions for SCD in sub-Saharan Africa. This region bears over 75% of the global burden of SCD, with more than 300,000 babies born annually with the disease, many of whom do not survive to the age of five due to a lack of early diagnosis and treatment.

The Role of the Consortium on Newborn Screening in Africa (CONSA)

Feasibility and implementation of newborn screening for SCD have shown promising results, despite challenges posed by limited resources and a high disease burden. The program involves collecting blood samples through heel pricks, preparing dried blood spots, and testing them using standardised techniques. This approach has been successfully implemented across several countries, including Ghana, Kenya, Liberia, Nigeria, Tanzania, Uganda, and Zambia.

Challenges and Feasibility in Implementation

Early identification through newborn screening for SCD allows for timely therapeutic interventions such as antibiotic prophylaxis, pneumococcal vaccinations, and other preventive measures. These interventions significantly improve the quality of life and longevity of children diagnosed with SCD. For instance, penicillin prophylaxis and pneumococcal vaccinations have been shown to reduce the risk of bacterial infections, a major cause of mortality in children with SCD.

Global Implications

Reducing global health disparities is one of the main outcomes of successful newborn screening programs for SCD in Africa. These initiatives can serve as models for other regions with high SCD prevalence, such as India and the Middle East. They highlight the importance of early diagnosis and intervention in reducing mortality rates and improving health outcomes for children with SCD globally.

International collaboration and resource sharing have proven essential in this effort. The involvement of organisations like ASH, the World Health Organization (WHO), and various national health missions enhances the value of collective action to address global health challenges. Best practices, resources, and expertise can help bridge the healthcare gap between the Global North and South.

Advancements in Healthcare Infrastructure

Advancements in healthcare infrastructure are essential for the sustainability of screening programs for SCD. Establishing robust healthcare systems, including specialised laboratories and trained personnel, can support these initiatives. Therefore, contributing to overall improvements in the quality of care in low- and middle-income countries.

Research and policy implications stemming from screening for SCD are also significant. Data collected can inform global policies and guidelines for managing SCD. Research into affordable, effective treatments, such as gene editing and optimised stem cell transplants, remains essential for resource-limited settings.

Conclusion: Global Implications and Future Directions

In summary, the success of newborn screening for SCD in Africa carries substantial global implications. It can reduce health disparities, boost international collaboration, strengthen healthcare infrastructure, and guide future SCD research and policy globally.

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.